$25+ Billion Antifungal Drugs Markets, 2030 by Drug Class, Infection Type, Therapeutic Indications, Dosage Forms – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering. The anti-fungal drugs market was valued at $16,572.1 million in 2020, and is estimated to reach $25,045.20 million by 2030, growing at a CAGR … [Read more…]

Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape” report has been added to ResearchAndMarkets.com’s offering. This reports provides a data-driven overview of the current and future competitive landscape in Waldenstrom Macroglobulinemia therapeutics. Synopsis In 2022, there will be more than 14,000 incident cases of WM across 16 pharmaceutical … [Read more…]

The Worldwide Dental Implants and Prosthesis Industry is Expected to Reach $16.3 Billion by 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dental Implants and Prosthesis – Market Insights, Competitive Landscape and Market Forecast-2027” report has been added to ResearchAndMarkets.com’s offering. The global dental implants and prosthesis market was valued at USD 10.42 billion in 2021, growing at a CAGR of 7.79 % during the forecast period from 2022 to 2027 to reach USD 16.35 … [Read more…]

Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study

HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the CE marking of its PCR kit which measures circulating microRNA-132 (miR-132) levels in the blood of patients receiving the company’s lead candidate CDR132L, an oligonucleotide-based miR-132 inhibitor. The company is currently conducting its Phase … [Read more…]

Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

– Study Results Validate the Hypothesis That TTR Silencing by an RNAi Therapeutic has the Potential to be an Effective Approach for Treating Cardiomyopathy of ATTR Amyloidosis – – Patisiran met Primary Endpoint, Demonstrating Significant Clinical Benefit on Functional Capacity (6-MWT) Compared to Placebo at Month 12 – – Patisiran Also met the First Secondary … [Read more…]

Genus plc Reports Preliminary Results for the Year Ended 30 June 2022

Continued Strategic Progress in Challenging Markets Webcast Available at 7:01AM BST, 2.01 EDT LONDON–(BUSINESS WIRE)–Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2022. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its … [Read more…]

Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression

Two separate analyses1,2 presented at the Migraine Trust International Symposium (MTIS) demonstrate the effectiveness of AJOVY▼(fremanezumab) for the treatment of migraine in patients with migraine and co-morbid depression Depression and anxiety are common co-morbidities experienced by around half of all patients with migraine3,4 and are associated with more pain, disability and a reduced quality of … [Read more…]

Sensorion to participate in the Inner Ear Biology Workshop in September 2022

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce Sensorion’s participation, in-person, in the Inner Ear Biology Workshop, taking place on September 10-13, 2022, in Trieste, … [Read more…]

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

SAINT-HERBLAIN, France & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe. Under the terms of the agreement, … [Read more…]

Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update

MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 15, 2022, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2022. Speakers during the … [Read more…]